Institute for Neuroplasticity Research

𝐃𝐚𝐭𝐚 𝐒𝐜𝐢𝐞𝐧𝐜𝐞 (𝐑𝐞𝐚𝐥 𝐖𝐨𝐫𝐥𝐝 𝐃𝐚𝐭𝐚) 𝐓𝐡𝐞 𝐛𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐢𝐬 𝐬𝐢𝐭𝐭𝐢𝐧𝐠 𝐨𝐧 𝐚 𝐠𝐨𝐥𝐝𝐦𝐢𝐧𝐞 𝐨𝐟 𝐫𝐞𝐚𝐥-𝐰𝐨𝐫𝐥𝐝 𝐝𝐚𝐭𝐚, 𝐲𝐞𝐭 𝐑𝐖𝐄 𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐨𝐧 𝐫𝐞𝐦𝐚𝐢𝐧𝐬 𝐜𝐡𝐫𝐨𝐧𝐢𝐜𝐚𝐥𝐥𝐲 𝐛𝐨𝐭𝐭𝐥𝐞𝐧𝐞𝐜𝐤𝐞𝐝.

Troriluzole, a third-generation tripeptide prodrug of riluzole, was advanced across four indications — spinocerebellar ataxia (SCA), generalized anxiety disorder (GAD), obsessive-compulsive disorder (OCD, twice), and Alzheimer’s disease — on the strength…

Thirteen million Americans take prescription sleep medications most days or every day.

𝐂𝐨𝐧𝐬𝐮𝐦𝐞𝐫 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐣𝐞𝐜𝐭𝐬 𝐄𝐱𝐩𝐞𝐧𝐬𝐞 𝐚𝐧𝐝 𝐍𝐮𝐢𝐬𝐚𝐧𝐜𝐞 𝐨𝐟 𝐌𝐞𝐝𝐢𝐜𝐚𝐥 𝐃𝐞𝐯𝐢𝐜𝐞 𝐏𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐢𝐧 𝐅𝐚𝐯𝐨𝐫 𝐨𝐟 𝐚 𝐒𝐞𝐥𝐟-𝐓𝐢𝐭𝐫𝐚𝐭𝐢𝐨𝐧 𝐇𝐞𝐮𝐫𝐢𝐬𝐭𝐢𝐜 𝐖𝐡𝐞𝐧 𝐕𝐚𝐩𝐢𝐧𝐠 𝐂𝐚𝐧𝐧𝐚𝐛𝐢𝐬 𝐄𝐱𝐭𝐫𝐚𝐜𝐭𝐬 (𝐎𝐢𝐥): 𝐝𝐞𝐞𝐩 𝐨𝐫 𝐬𝐡𝐚𝐥𝐥𝐨𝐰 𝐩𝐮𝐟𝐟, 𝐦𝐨𝐫𝐞 𝐨𝐫 𝐟𝐞𝐰𝐞𝐫 𝐩𝐮𝐟𝐟𝐬, 𝐰𝐡𝐚𝐭 𝐠𝐢𝐯𝐞𝐬 𝐫𝐞𝐥𝐢𝐞𝐟 𝐭𝐨 𝐨𝐧𝐞 𝐢𝐧𝐝𝐢𝐯𝐢𝐝𝐮𝐚𝐥 𝐢𝐬 𝐝𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐭 𝐟𝐨𝐫 𝐚𝐧𝐨𝐭𝐡𝐞𝐫.

𝐓𝐚𝐫𝐠𝐞𝐭𝐢𝐧𝐠 𝐓𝐃𝐏-𝟒𝟑 𝐢𝐧 𝐀𝐋𝐒: 𝐑𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐡𝐮𝐫𝐝𝐥𝐞𝐬, 𝐭𝐫𝐢𝐚𝐥 𝐝𝐞𝐬𝐢𝐠𝐧 𝐝𝐞𝐟𝐢𝐜𝐢𝐞𝐧𝐜𝐢𝐞𝐬, 𝐚𝐧𝐝 𝐭𝐡𝐞 𝐜𝐚𝐮𝐬𝐚𝐥 𝐞𝐯𝐢𝐝𝐞𝐧𝐜𝐞 𝐠𝐚𝐩 𝐟𝐨𝐫 𝐂𝐓𝐱𝟏𝟎𝟎𝟎.

𝗪𝗮𝗶𝘁 𝗮 𝗺𝗶𝗻𝘂𝘁𝗲!

In the 1950s, my physicist father, Eugene Guth, met with Albert Einstein at the Institute for Advanced Study to discuss unified field theory.

This week on CounterSpin Podcast: Janine Jackson: Corporate news media obscure it, almost like it’s their job, but we still understand that laws and policies land on differently situated people differently.

The post-2022 period revealed that genuinely novel non-amyloid mechanisms—TREM2 agonism, GLP-1 receptor stimulation, filamin A modulation, and progranulin/sortilin restoration—also failed to produce clinical benefit at scale despite confirmed target engag…

A new oral pill drug approved by the FDA for treatment of pancreatic cancer extends life on average 13.2 months compared to 6.7 months for harsh chemotherapy.

BRIAHNA JOY GRAY: Let’s talk about something like Medicare for All, which Bernie has already done the work of making popular.

AAV9 immunogenicity as a scalability trap.

A methodological audit: Where the glasses may be rose-colored https://authors.elsevier.com/a/1nYxN4r9Rkz1wZ The open-label problem KOANEWA is a Phase Ib, open-label, non-randomized, single-dose study (ClinicalTrials.gov identifier: NCT07401121).

Guth MAS.